This animal study, conducted by five independent medical doctors, was performed on swine by completely severing femoral arteries. The results were peer-reviewed, it was presented at a major medical conference, and it has been published in a major medical journal.
A NAMSA GLP Independent Laboratory Animal Study was conducted on CoaguVet™ to prove its safety.
Conclusion:
The objective of this study was to evaluate the local tissue response to CoaguVet™ hemostatic powder in a chronic rabbit subcutaneous implant model. There were no adverse events, clinical observations, abnormal clinical pathology, or abnormal gross pathology attributed to the test article. To paraphrase the study, all animals observed after the 4-week period were in the same condition as when they started. The CoaguVet™ Pet powder in the animals’ bodies had no adverse effect on any of the animals or on any of the sites.
Summary:
The in-life assessment for each animal was clinically normal upon entering the study and all animals remained healthy during the in-life portion of the study. There were no adverse events noted during the study. According to the physical examinations, the clinical pathology results, the daily observations, the procedures, and the in-life assessment all animals in this study demonstrated adequate health to assess the objective of the study.
The powder was safely absorbed by the animals’ bodies.
